Glaukos Co. (NYSE:GKOS – Get Free Report) COO Joseph E. Gilliam sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $96.07, for a total value of $480,350.00. Following the sale, the chief operating officer now owns 119,802 shares of the company’s stock, valued at $11,509,378.14. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Glaukos Stock Performance
Shares of GKOS stock opened at $96.42 on Tuesday. The stock’s 50-day moving average is $83.26 and its two-hundred day moving average is $74.99. The firm has a market cap of $4.71 billion, a price-to-earnings ratio of -35.84 and a beta of 1.11. Glaukos Co. has a 1 year low of $44.26 and a 1 year high of $97.24. The company has a debt-to-equity ratio of 0.74, a quick ratio of 5.36 and a current ratio of 5.95.
Institutional Investors Weigh In On Glaukos
Several hedge funds have recently made changes to their positions in the business. Xponance Inc. lifted its position in Glaukos by 4.1% in the fourth quarter. Xponance Inc. now owns 2,879 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 113 shares during the period. American International Group Inc. lifted its position in shares of Glaukos by 0.6% during the 2nd quarter. American International Group Inc. now owns 25,246 shares of the medical instruments supplier’s stock valued at $1,798,000 after acquiring an additional 145 shares during the period. Corient Private Wealth LLC lifted its position in shares of Glaukos by 0.7% during the 4th quarter. Corient Private Wealth LLC now owns 24,775 shares of the medical instruments supplier’s stock valued at $1,969,000 after acquiring an additional 163 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Glaukos by 4.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,353 shares of the medical instruments supplier’s stock valued at $310,000 after acquiring an additional 200 shares during the period. Finally, American Century Companies Inc. lifted its position in shares of Glaukos by 3.1% during the 1st quarter. American Century Companies Inc. now owns 6,878 shares of the medical instruments supplier’s stock valued at $339,000 after acquiring an additional 207 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.
Wall Street Analyst Weigh In
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
- Five stocks we like better than Glaukos
- What are stock market earnings reports?
- 3 attractive stocks that insiders are buying
- CD Calculator: Certificate of Deposit Calculator
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Growth Stocks: What They Are, Examples and How to Invest
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.